

**CERTIFICATE OF MAILING**


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Sammy G. Duncan, Jr.  
Type or print name

[Signature]  
Signature

6/22/04  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF

ROBICHAUD ET AL.

APPLICATION NO: 10/786,935

FILED: FEBRUARY 25, 2004

FOR: SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES

Mail Stop **Box Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/594,008 filed April 15, 2003, and parent Application No. 10/370,872, filed 5/13/04, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
\_\_\_\_\_  
Sammy G. Duncan Jr. Ph.D.  
Attorney for Applicants  
Reg. No. 46,675

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6270

Date: 6/22/04

Form PTO-1449  
(Reproduced)U. S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
PH-7218A CIPSERIAL NO.  
10/786,935INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Robichaud et al

FILING DATE

2/25/04

GROUP

1624

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5 5 1 2 5 7 5	4/30/1996	Jacobs et al			
	AB	5 6 5 4 1 3 9	8/5/1997	Lappalainen et al			
	AC	5 9 0 2 8 1 5	5/11/1999	Olney et al			
	AD	5 9 0 8 8 3 0	6/1/1999	Smith et al			
	AE	6 1 0 7 3 2 4	8/22/2000	Behan et al			
	AF	6 1 4 0 5 0 9	10/31/2000	Behan et al			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AG							
	AH							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	Bickerdike MJ, Vickers, SP, Dourish CT, (1999) 5-HT <sub>2C</sub> receptor modulation and the treatment of obesity. Diabetes, Obesity and Metabolism 1:207-214
	AJ	Tecott LH, et al. (1995) Eating disorder and epilepsy in mice lacking 5-HT <sub>2C</sub> serotonin receptors. Nature (London) 374:542-546
	AK	Cryan JF, Lucki I, (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine <sub>2C</sub> receptors. J. Pharmacol. Exper. Ther. 295:1120-1126
	AL	Millan MJ, Peglioni JL, Lavielle G, Perrin-Monneyron S, (1997) 5-HT <sub>2C</sub> receptors mediate penile erection in rats: actions of novel and selective agonists and antagonists. Eur. J. Pharmacol. 325:9-12
	AM	Martin JR, et al. (1998) 5-HT <sub>2C</sub> receptor agonists: Pharmacological characteristics and therapeutic potential. J. Pharmacol. Exper. Ther. 286:913-924
	AN	Meltzer HY. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2):1065-1155

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Reproduced)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
PH-7218 A CIPSERIAL NO.  
10/786,935INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT  
Robichaud et alFILING DATE  
2/25/04GROUP  
1624

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA'						
AB'						
AC'						
AD'						
AE'						
AF'						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
AG'							
AH'							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI'	Curzon et al, Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability, TIPS, Vol. 18, 1997; 21-25
AJ'	Mora et al, Role of 5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> Receptor subtypes in the Two Types of Fear Generated by the Elevated T-Maze, Pharma. Biolchem. & Behavior, Vol. 58, No. 4, 1997; 1051-1057
AK'	Jenck et al, Antiaversive effects of 5HT <sub>2C</sub> receptor agonists and fluoxetine in a model of panic-like anxiety in rats, European Neuropsychopharmacology, 8, 1998; 161-168
AL'	Leysen, Selective 5-HT <sub>2c</sub> agonists as potential antidepressants, Drugs, 1999, 2(2); 109-120
AM'	Jenck et al, The role of 5-HT <sub>2c</sub> receptors in affective disorders, Exp. Opin. Invest. Drugs, 1998, 7(10); 1587-1599
AN'	Kennett, 5-HT drugs and eating disorders, I Drugs, 1998, Vol. 1, No. 4; 456-470

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Reproduced)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

PH-7218A CIP

SERIAL NO.

10/786,935

## INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Robichaud et al

FILING DATE

2/25/04

GROUP

1624

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA"	3 2 9 9 0 7 8	1/17/67	Pachter			
AB"						
AC"						
AD"						
AE"						
AF"						

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AG"					
AH"					

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI"	Brewerton, Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine, Clin. Pharmacol. Ther., 1988, 605-609
AJ"	Kahn et al, m-Chlorophenylpiperazine as a probe of serotonin function, Biol. Psychiatry, 1991; 30: 1139-1166
AK"	Gibson et al, Evidence that mCPP-induced Anxiety in the Plus-maze is mediated by Postsynaptic 5-HT <sub>2c</sub> receptors but not by sympathomimetic effects, Neuropharmacology, Vol. 33, No. 3, 4, 1994; 457-465
AL"	
AM"	
AN"	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.